![Kimberly Nearing](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kimberly Nearing
Director/Miembro de la Junta en Ethismos Research, Inc. .
Perfil
Kimberly Nearing currently works at Ethismos Research, Inc., as Director from 2020.
Cargos activos de Kimberly Nearing
Empresas | Cargo | Inicio |
---|---|---|
Ethismos Research, Inc.
![]() Ethismos Research, Inc. BiotechnologyHealth Technology Ethismos Research, Inc. is a clinical-stage drug development company located in an undisclosed location. Ethismos is developing pharmaceutical treatments for pain, depression, and substance use disorders. Amitifadine is different from opioids and addiction treatments because it is not believed to be addictive, nor is it a stimulant or an opioid. Ethismos plans to commence phase 2 amitifadine clinical trials for opioid-sparing and facilitation of opioid taper as a non-opioid analgesic in chronic pain patients treated with long-term opioids. The American company is also exploring amitifadine trials in depression maintenance post-ketamine treatment, methamphetamine dependence, and nicotine cessation. The private company was founded by Anthony A. McKinney and he has been the CEO since incorporation. The company is continuing the development of the patented small molecule, amitifadine, a triple reuptake inhibitor, originally developed by euthymics bioscience, and acquired by ethismos in 2017. | Director/Miembro de la Junta | 01/01/2020 |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Ethismos Research, Inc.
![]() Ethismos Research, Inc. BiotechnologyHealth Technology Ethismos Research, Inc. is a clinical-stage drug development company located in an undisclosed location. Ethismos is developing pharmaceutical treatments for pain, depression, and substance use disorders. Amitifadine is different from opioids and addiction treatments because it is not believed to be addictive, nor is it a stimulant or an opioid. Ethismos plans to commence phase 2 amitifadine clinical trials for opioid-sparing and facilitation of opioid taper as a non-opioid analgesic in chronic pain patients treated with long-term opioids. The American company is also exploring amitifadine trials in depression maintenance post-ketamine treatment, methamphetamine dependence, and nicotine cessation. The private company was founded by Anthony A. McKinney and he has been the CEO since incorporation. The company is continuing the development of the patented small molecule, amitifadine, a triple reuptake inhibitor, originally developed by euthymics bioscience, and acquired by ethismos in 2017. | Health Technology |
- Bolsa de valores
- Insiders
- Kimberly Nearing